Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Apolipoprotein E Christchurch Variant (APOE3Ch)
- Target
- APOE3Ch
- Molecular classification
- Apolipoprotein, Lipid Transport Protein
01
Overview
The Apolipoprotein E (ApoE) Christchurch variant is a rare genetic mutation in the APOE gene, characterized by an arginine-to-serine substitution at position 136 (R136S). This variant alters receptor binding properties and modulates microglial and astrocyte responses, leading to potential protection against Alzheimer's disease by suppressing tau propagation and reducing astrocyte reactivity. It was first identified in a patient with type III hyperlipoproteinemia from Christchurch, New Zealand. Recent research suggests APOE Christchurch‐mimetic therapeutic antibody reduces APOE aggregation.
- Other names
- APOE R136SAPOE3 ChristchurchAPOE Christchurch (R136S)APOE3Ch(R136S)
02
Mechanism of action
APOE Christchurch-mimetic therapeutic antibody reduces APOE aggregation
03
Biological functions
Lipid metabolismReceptor bindingMicroglial modulationAstrocyte modulationTau propagation suppression
04
Disease associations
Type III hyperlipoproteinemiaAlzheimer's disease (reduced risk/resilience)
05
Safety considerations
Potential for enhancing disease-associated microglial reactivity in amyloid modelsRare variant with limited understanding of long-term effects
06
Biomarkers
APOE genotypeAmyloid plaque accumulationTau pathologyCognitive decline
Beyond the preview
Go deeper on Apolipoprotein E Christchurch Variant (APOE3Ch).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apolipoprotein E Christchurch Variant (APOE3Ch).